Table 1. Characterization of Hippocampus and HPA-axis.

		Cx (N=5-13)	LBW (N=8-14)	SSRI-LBW (N=8-16)	*Post hoc test P-values*
Adrenal Corticosterone Release					
RST AUC 60 to 90 minutes (ng/*minutes)		12470±1270	19440±1240*	11180±1030	**P<0.01 vs. Cx & vs. SSRI-LBW*
24 H U-Corticosterone (nmol/[24 H*kg b.w.])		10.1±0.6	13.9±1.2†	8.1±0.5	*†P<0.05 vs. Cx & P<0.01 vs. SSRI-LBW*
Pituitary ACTH Release					
Plasma ACTH concentrations (pg/ml)	9 a.m.	15.96±0.65	18.13±1.40	16.87±1.01	---
	9 p.m.	13.18±0.37‡	15.53±1.42	12.89±0.37‡	*‡P<0.05 vs. 9a.m.*
Hypothalamic Corticosteroid Feedback					
HSD1 mRNA Expression (% of Cx)		100.0±20.4	82.5±16.1	73.6±13.7	---
MR mRNA Expression (% of Cx)		100.0±21.4	501.7±160.4§	205.8±60.0	*§P<0.05 vs. Cx*
GR mRNA Expression (% of Cx)		100.0±15.8	123.9±15.8	121.6±46.5	---
Hippocampal Corticosteroid Feedback					
HSD1 mRNA Expression (% of Cx)		100.0±15.5	122.2±25.3	67.5±8.6	---
MR mRNA Expression (% of Cx)		100.0±10.0	123.2±13.3#	85.5±8.9	*# P=0.0725 vs. Cx*
GR mRNA Expression (% of Cx)		100.0±14.1	122.5±11.1	88.1±10.9	---

Data are means±sem. P-values for comparisons reflect the results for the *post hoc* analysis which has been carried out only when the one way of analysis of variance test (ANOVA) results in a p-value less than 0.05.
RST: Restrain Stress Test (Figure 1). 24 H U-Corticosterone: 24 hour urinary corticosterone excretion.

Table 2. Oral Glucose Tolerance Test (OGTT).

	Cx (N=13)	LBW (N=11)	SSRI-LBW (N=13)	Post hoc test P-values
Oral Glucose Tolerance Test				
Fasting Glucose Concentrations (mmol/l)	**4.55±0.13**	**4.37±0.11**	**4.72±0.13**	---
Fasting Insulin Concentrations (mU/l)	**7.83±1.12**	**26.93±5.24***	**11.83±2.17**	*P<0.01 vs. Cx & P<0.05 vs. SSRI-LBW
OGTT Total AUC$_{glucose}$ (mmol/l glucose*min)	**871±20**	**898±23**	**767±29†**	†P<0.05 vs. Cx & P<0.01 vs. LBW
OGTT Total AUC$_{insulin}$ (mU/l insulin*min)	**1,542±39**	**3,738±79‡**	**1,996±37**	‡P<0.01 vs. Cx & SSRI-LBW
Insulin-Sensitivity Index (ISI) (expressed as % of Cx)	**100.0±10.3**	**51.1±6.3§**	**85.0±.8.1**	§P<0.01 vs. Cx & P<0.05 vs. SSRI-LBW

Data are means±sem. P-values for comparisons reflect the results for the *post hoc* analysis which has been carried out only when the one way of analysis of variance test (ANOVA) results in a p-value less than 0.05.

Table 3. Muscle Glucose Metabolism.

	Cx (N=5-14)	LBW (N=8-9)	SSRI-LBW (N=6-8)	Post hoc test P-values
Glycogen & GLUT4-Protein Content in Red (RG) and White (WG) Gastrocnemius Muscle Tissue				
Basal Glycogen WG (μmol/g muscle w.w.)	**38.8±1.3**	**40.5±1.7**	**42.9±1.8**	---
Basal Glycogen RG (μmol/g muscle w.w.)	**31.4±2.2***	**33.8±1.7***	**32.4±2.3***	†P<0.05 vs. WG
Total GLUT4 Content WG (arbitrary units)	**9.89±3.36**	**10.32±0.90**	**9.97±0.58**	---
Total GLUT4 Content RG (arbitrary units)	**13.93±0.71***	**16.38±1.92***	**13.22±0.98***	†P<0.05 vs. WG
PkB Ser (473) Phosphorylation in Red Gastrocnemius Muscle Tissue				
Basal Phosphorylation (arbitrary units)	**29,568±3,239**	**31,691±4,901**	**22,459±4,429**	---
ClampPhosphorylation (arbitrary units)	**69,596±10,600†**	**56,729±7,641†**	**76,127+8,287†‡**	†P<0.05 vs. Basal ‡ P<0.10 vs. LBW
Insulin-Stimulated Increase from Basal (%)	**135±4**	**79±24**	**239±43§**	§P<0.05 vs. LBW

Data are means±sem. P-values for comparisons reflect the results for the *post hoc* analysis which has been carried out only when the one way of analysis of variance test (ANOVA) results in a p-value less than 0.05.

Tables. LBW-rats & Exposure to an SSRI Antidepressant, Esben S. Buhl et al., 2009.

For online publication.

Primer sequences for PCR experiments (Buhl ES et al, 2009)	
mRNA Expression Studies in Liver Tissue	
G6Pase forward primer	AGG GTA AAA GAA AAG AGC GTT G
G6Pase reverse primer	GTA GAC ATG GCT TGC ATA TGG T
PEPCK forward primer	CAG GAA GTG AGG AAG TTT GTG G
PEPCK reverse primer	ATG ACA CCC TCC TCC TGC AT
GAPDH forward primer	TCACCACCATGGAGAAGGC
GAPDH reverse primer	GCTAAGCAGTTGGTGGTGCA
mRNA Expression Studies in Brain Tissue	
GR forward primer	GGTACTCAAGCCCTGGAATG
GR reverse primer	CAATCGTTTCTTCCAGCACA
MR forward primer	TGAGTTCCTTCCCACCTGTC
MR reverse primer	AAGCCTCATCTCCACACACC
HSD1 forward primer	CTCTCTGTGTCCTCGGCTTC
HSD1 reverse primer	TTCCATGATCCTCCTTCCTG
18S forward primer	ACGGACCAGAGCGAAAGCAT
18S reverse primer	TGTCAATCCTGTCCGTGTCC
Beta-Actin forward primer	TGTCACCAACTGGGACGATA
Beta-Actin reverse primer	GGGGTGTTGAAGGTCTCAAA
Cyclophilin A forward primer	AGCACTGGGGAGAAAGATT
Cyclophilin A reverse primer	AGCCACTCAGTCTTGGCAGT
GAPDH forward primer	TCACCACCATGGAGAAGGC
GAPDH reverse primer	GCTAAGCAGTTGGTGGTGCA
Hmbs forward primer	TCCTGGCTTTACCATTGGAG
Hmbs reverse primer	TGAATTCCAGGTGAGGGAAC
Hprt1 forward primer	GCAGACTTTGCTTTCCTTGG
Hprt1 reverse primer	CGAGAGGTCC TTTTCACCAG
Rpl13A forward primer	ACAAGAAAAAGCGGATGGTG
Rpl13A reverse primer	TTCCGGTAATGGATCTTTGC
Ywhaz forward primer	TTGAGCAGAAGACGGAAGGT
Ywhaz reverse primer	GAAGCATTGGGGATCAAGAA

G6Pase: glucose-6-phosphatase; PEPCK: Phosphor-enol-pyruvate-carboxy-kinase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GR: Glucocorticoid-receptor; MR: Mineralo-corticoid-receptor; 18S: 18s subunit ribosomal RNA; HSD1: 11β hydroxysteroid dehydrogenase 1; Hmbs : Hydroxy-methylbilane synthase; Hprt1: Hypoxanthine guanine phosphoribosyl transferase 1; Rpl13A: Ribosomal protein L13A; Ywhaz :Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta;